Cargando…
Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHO...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yeungnam University College of Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/ https://www.ncbi.nlm.nih.gov/pubmed/31620574 http://dx.doi.org/10.12701/yujm.2018.35.1.76 |
_version_ | 1783457792188743680 |
---|---|
author | Cho, Hee-Jeong Seo, Sang-Kyung Baek, Dong Won Park, Sung-Woo Lee, Yoo-Jin Sohn, Sang-Kyun Lee, Ho-Sup Lee, Won Sik Lee, Ji Hyun Kim, Sung Hyun Moon, Joon-Ho |
author_facet | Cho, Hee-Jeong Seo, Sang-Kyung Baek, Dong Won Park, Sung-Woo Lee, Yoo-Jin Sohn, Sang-Kyun Lee, Ho-Sup Lee, Won Sik Lee, Ji Hyun Kim, Sung Hyun Moon, Joon-Ho |
author_sort | Cho, Hee-Jeong |
collection | PubMed |
description | BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHODS: One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group. RESULTS: Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS. CONCLUSION: A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM. |
format | Online Article Text |
id | pubmed-6784679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Yeungnam University College of Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-67846792019-10-16 Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen Cho, Hee-Jeong Seo, Sang-Kyung Baek, Dong Won Park, Sung-Woo Lee, Yoo-Jin Sohn, Sang-Kyun Lee, Ho-Sup Lee, Won Sik Lee, Ji Hyun Kim, Sung Hyun Moon, Joon-Ho Yeungnam Univ J Med Original Article BACKGROUND: Elderly patients with multiple myeloma (MM) are vulnerable to adverse events (AEs). This study evaluated adherence to chemotherapy and treatment outcomes in elderly patients treated with a frontline bortezomib (BTZ), melphalan, and prednisone (VMP) regimen and regimens without BTZ. METHODS: One-hundred and forty elderly patients who were diagnosed with MM from March 2007 to March 2015 were included in this retrospective study. To evaluate regimen adherence, patients who were treated with more than 4 cycles were assigned to the good adherence group. RESULTS: Among the 140 patients, 71 were treated with a frontline VMP and 69 with non-BTZ regimens. The median age was 71 years (range, 65-90 years). The VMP group showed a higher complete response rate than the non-BTZ group: 26.8% vs. 7.2%. More patients in the VMP group achieved ≥very good partial response (VGPR) and ≥PR. In the VMP group, 27 patients (38.0%) received less than 4 cycles. The VMP good adherence group showed a higher 3-year overall survival (OS) rate (70.9%) than the poor adherence group (60.2%, p=0.059). In the multivariate analysis, treatment with ≥4 cycles of VMP was a favorable factor for OS. CONCLUSION: A good adherence to a frontline VMP regimen resulted in favorable long-term survival. Adequate management of AEs will be needed to achieve favorable outcomes in elderly patients with MM. Yeungnam University College of Medicine 2018-06-30 /pmc/articles/PMC6784679/ /pubmed/31620574 http://dx.doi.org/10.12701/yujm.2018.35.1.76 Text en Copyright © 2018 Yeungnam University College of Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Cho, Hee-Jeong Seo, Sang-Kyung Baek, Dong Won Park, Sung-Woo Lee, Yoo-Jin Sohn, Sang-Kyun Lee, Ho-Sup Lee, Won Sik Lee, Ji Hyun Kim, Sung Hyun Moon, Joon-Ho Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title_full | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title_fullStr | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title_full_unstemmed | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title_short | Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
title_sort | chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784679/ https://www.ncbi.nlm.nih.gov/pubmed/31620574 http://dx.doi.org/10.12701/yujm.2018.35.1.76 |
work_keys_str_mv | AT choheejeong chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT seosangkyung chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT baekdongwon chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT parksungwoo chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT leeyoojin chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT sohnsangkyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT leehosup chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT leewonsik chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT leejihyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT kimsunghyun chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen AT moonjoonho chemotherapyadherenceisafavorableprognosticfactorforelderlypatientswithmultiplemyelomawhoaretreatedwithafrontlinebortezomibcontainingregimen |